-
drugs that target the HER2 protein
10 Jul 2025 20:31 GMT
… This drug is a pill taken … medicines for high blood pressure.
Because these drugs can cause heart damage, doctors … anastrozole (or if the cancer started growing shortly after treatment with these drugs … treatment with this drug.
This drug is taken as pills …
-
Suspending the NHS medicines repurposing programme in England is a missed opportunity
02 Jul 2025 17:16 GMT
… Burn, geneticist5
1MRC Clinical Trials Unit, University College … challenge.
Pharmaceutical companies support research on medicines when they … had identified that anastrozole was effective in preventing … 15 million in treatment costs.
Drug repurposing is not …
-
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review
30 Jun 2025 09:58 GMT
… dose-seeking clinical trial that recruited 15 postmenopausal … -drug combination was not discussed, necessitating further trials … relief by suspending medication or reducing the … anastrozole versus placebo plus letrozole or anastrozole as first-line treatment …
-
Cardio-Oncology Considerations for Breast Cancer: Risk Stratification, Monitoring, and Treatment
26 Jun 2025 23:48 GMT
… AIs; eg, letrozole, anastrozole, exemestane). More than 80% … of randomized controlled trials showed no increase … trial subsequently demonstrated that initiation of cardioprotective medications in patients undergoing treatment … the role of statins in reducing the …
-
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
26 Jun 2025 23:48 GMT
… 3 years) plus an NSAI (anastrozole 1 mg/day or … after the 3-year ribociclib treatment duration, with increasing absolute benefit …
-
Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer
03 Jun 2025 12:31 GMT
… treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole … approval from China’s National Medical Products Administration. In MBC, … benefit across three phase III trials. The NCCN Guidelines also … collaboration with Astex Pharmaceuticals.
-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
01 Jun 2025 12:10 GMT
… free survival (PFS). The trial evaluated switching to the … The New England Journal of Medicine.
Results showed the camizestrant … or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in … in Phase III trials for the treatment of HR-positive …
-
Drug-defying breast cancers spotted early in blood test study
02 Jun 2025 02:03 GMT
… New England Journal of Medicine.
Breast cancer specialists … will allow doctors to squelch drug-resistant cancers before … were taking the standard treatment. One drug, an aromatase inhibitor, … One standard aromatase inhibitor, anastrozole, can cost less than …
-
Keeping Up With The Growing Number of Treatments for Breast Cancer
22 Apr 2025 18:19 GMT
… premenopausal women or aromatase inhibitors (anastrozole, letrozole, exemestane) for postmenopausal … drug interactions, and the importance of completing the full course of treatment … , guiding patients through complex treatment regimens, and helping manage …
-
Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies
07 Apr 2025 09:01 GMT
… to identify randomized trials, nonrandomized trials, and single … Neuromodulatory medications included centrally active medications (eg, antidepressants, anticonvulsants … study. J Nat Remedies. 2019;19: … Treatment reduces joint morbidities induced by anastrozole …